Category
Molecular Genetic Pathology & Cytogenetics
Sub Category
Oncology (Solid Tumors)
Synonym/Aliases
Kras Mutation Analysis; Kras Mutation Detection; Kras Codons 12, 13
Abbreviations
N/A
Type
Individual Test
Results
RESULTS READY WITHIN 10 DAYS
Method
PCR / SEQUENCING
Temp
KEPT AT ROOM TEMPERATURE
Setup
BATCHED
Components Parameters
- N/A
PRE-ANALYTIC CONSIDERATIONS
Test Ordering Instructions
FILL OUT TEST REQUEST FORM FULLY & LEGIBLY. CLINICAL HISTORY, HISTOLOGY (H&E) REPORT ARE MANDATORY.
Patient preparation
- N/A
Sample type
TUMOR POSITIVE FORMALIN-FIXED, PARAFFIN-EMBEDDED (FFPE) BLOCK.
Container/ preservative
FORMALIN FIXED, PARAFFIN EMBEDDED BLOCKS [PREFERRED]. ALTERNATIVELY, 5 MICRONS UNSTAINED SECTIONS ON POSITIVELY-CHARGED SLIDES (≥FOUR SLIDES) & 1 MATCHING H&E SLIDE.
Sample volume
SUFFICIENT RESIDUAL TISSUE/ TUMOR MUST BE AVAILABLE ON THE BLOCK
Rejection criteria
LABELING ISSUE (UNLABELED/ MISLABELED); MISSING REQUEST FORM; MISMATCH BETWEEN REQUEST FORM & SAMPLE DETAILS; MISSING AGE/ GENDER; WRONG SAMPLE TYPE; INSUFFICIENT SAMPLE; DECALCIFIED SAMPLES.
Other Instructions
- N/A
Reference intervals
INTERPRETIVE DATA IS PROVIDED ON THE REPORT.
Clinical Utility
DETECTS PRESENCE OR ABSENCE OF KRAS CODON 12/13 (EXON 2) MUTATIONS. A PREDICTIVE/ THERANOSTIC MARKER FOR COLORECTAL & NON-SMALL CELL LUNG CANCER. PATIENTS WITH POSITIVE RESULTS INDICATE RESISTANCE TO ANTI-EGFR THERAPY E.G. CETUXIMAB (ERBITUX), PANITUMUMAB (VECTIBIX).
Test Limitations / Confounders
RESISTANCE TO ANTI-EGFR THERAPY MAY OCCUR DUE TO KRAS CODON 61, BRAF MUTATIONS